MCRB

Seres Therapeutics (MCRB)

About Seres Therapeutics (MCRB)

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Details

Daily high

$6.85

Daily low

$6.02

Price at open

$6.73

52 Week High

$29.98

52 Week Low

$5.31

Market cap

59.2M

Dividend yield

0.00%

Volume

154,449

Avg. volume

127,948

P/E ratio

-1.22

Seres Therapeutics News